On Wednesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: NRG Energy, (NYSE:NRG), ZIOPHARM Oncology, (NASDAQ:ZIOP), Pioneer Energy Services,, (NYSE:PES), Gordmans Stores, (NASDAQ:GMAN)
NRG Energy, (NYSE:NRG), with shares declined -6.31%, closed at $23.60.
ZIOPHARM Oncology, (NASDAQ:ZIOP), with shares dropped -6.22%, settled at $10.10.
Pioneer Energy Services,, (NYSE:PES), with shares dipped -6.09%, and closed at $5.09.
Gordmans Stores, (NASDAQ:GMAN), plummeted -6.02%, and closed at $7.80, hitting new 52-week high of $8.70.
Latest NEWS regarding these Stocks are depicted underneath:
NRG Energy, Inc. (NYSE:NRG)
NRG Energy, Inc. (NRG), fell on Wednesday, as the Federal Energy Regulatory Commission (FERC) decided not to approve a Capacity Performance Plan presented by PJM Interconnection.
The commission issued a deficiency letter in response to PJM’s application on Wednesday and requested that the organization answer further questions about the initiative. The FERC is not predictable to decide on the application before PJM answers the questions.
The Capacity Performance Plan would “provide stronger performance incentives and more operational availability and diversity during peak power system conditions,” according to PJM.
PJM also declared it created the plan in response to questions regarding the performance of its generation fleet in recent years, especially during cold weather.
NRG Energy, Inc., together with its auxiliaries, operates as a power corporation. The corporation provides electricity; system power, distributed generation, solar and wind products, backup generation, storage and distributed solar, demand response, energy efficiency, and on-site energy solutions; carbon administration and specialty services; and various energy services, such as operations, maintenance, technical, development, and asset administration services.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. (ZIOP), and Intrexon Corporation (XON) declared their oncology programs will be strengthened through Intrexon’s new global partnership focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, counting upfront payment, milestones and royalties, equally with ZIOPHARM.
Under the partnership Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its contract with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM’s other oncology programs will continue through its Exclusive Channel Partnership(ECC) with Intrexon.
ZIOPHARM Oncology, Inc., a biotechnology corporation, focuses on acquiring, developing, and commercializing cancer therapies. The corporation is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.
Pioneer Energy Services Corp. (NYSE:PES)
On March 27, Deutsche Bank Research Firm, has downgraded Pioneer Energy Services Corp. (PES), from “Buy” to “Hold.”
On the same day, the company declared that it will release its first quarter 2015 financial results before the market opens on Thursday, April 30. In conjunction with the release, Pioneer has planned a conference call that will be broadcast live over the Internet the same day starting at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Investors may take part in the call either by phone or audio webcast.
Pioneer Energy Services Corp., through its auxiliaries, provides drilling services and production services to oil and gas exploration and production companies in the United States and Colombia.
Gordmans Stores, Inc. (NASDAQ:GMAN)
Gordmans Stores, Inc. (GMAN), stock has volatility for the week is 12.66%, while for the month remained 7.71%. The company holds consensus target price of $5.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.18 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -143.90% and Annual EPS growth for the past 5 years is considered as -16.90%.
The mean recommendation of analysts for this stock is 2.70. (where 1=Buy, 5=Sale).
Gordmans Stores, Inc. operates department stores under the Gordmans name in the United States. Its merchandise selection comprises a range of apparel, footwear, and home fashions products, in addition to accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
